A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. by Anderson, H. et al.
British Journal of Cancer (1996) 74, 460-462
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
A phase I study ofa 24 hour infusion ofgemcitabine in previously untreated
patients with inoperable non-small-cell lung cancer
H Anderson', N Thatcher', J Walling2 and H Hansen3
1CRC Department ofMedical Oncology, University ofManchester, Christie Hospital and Wythenshawe Hospital, Manchester UK;
2Lilly Industries Ltd, Basingstoke, UK; 3Rigshospitalet, Copenhagen, Denmark.
Summary A phase I study to determine the maximum tolerated dose and toxicity of gemcitabine when given
as a 24 h infusion to patients with inoperable non-small-cell lung cancer (NSCLC). A total of 24 patients with
unresectable stage IIIa-IV NSCLC were entered into the study. Gemcitabine was administered as a 24 h
infusion on days 0, 7 and 14. Courses of therapy were repeated every 28 days. There were 16 males and 8
females with a median age of 51 years (range 40-73 years). The WHO performance score was 1 (21 patients)
or 2 (3 patients). The TNM stage was IIIa (6), IIIb (10) and IV (8). Three patients were entered at each dose
level with six at the maximum tolerated dose (MTD). Dose levels were 10, 20, 40, 80, 120, 180 and
210 mg m-2. The MTD was 180 mg m-2 and dose-limiting toxicity was neutropenia and lethargy. Partial
response was observed in five (21%) patients (95% CI 7-42%) lasting 10, 14, 18, 47 and 51 + weeks. The
maximum tolerated dose of gemcitabine given as a 24 h infusion was 180 mg m-2
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Gemcitabine (2'2'difluorodeoxycytidine), is a pyrimidine
antimetabolite, structurally related to cytosine arabinoside
(Ara-C). Gemcitabine has significantly greater activity against
a wide range of murine and human solid tumour models
including X-5563 myeloma, B-16 melanoma and CA-755
adenocarcinoma than Ara-C (Hertel et al., 1990).
Gemcitabine is phosphorylated by deoxycytidine kinase
into the active diphosphate (GDP) and triphosphate (GTP)
metabolites. After GDP or GTP incorporation into DNA one
further nucleotide is added then DNA chain termination
ceases (Huang et al., 1991). Ara-C is similarly converted into
its triphosphate. At equimolar concentrations of the parent
drug intracellular concentrations of gemcitabine triphosphate
are 20-fold greater than Ara-C triphosphate (Heinemann et
al., 1988). However, with a unique mode of self-potentiation,
gemcitabine triphosphate inhibits the deaminase that is
responsible for conversion to the uracil metabolite (Xu et
al., 1990).
Phase I studies of gemcitabine have shown that toxicity is
schedule-dependent. Patients treated with a daily schedule for
5 days every 3 weeks experienced fever, flu-like symptoms
and dose-limiting hypotension at 12 mg m-2 (O'Rourke et
al., 1994). A twice-weekly schedule for 3 weeks repeated every
4 weeks showed dose-limiting toxicity at 75 mg m-2 with
thrombocytopenia and flu symptoms (Poplin et al., 1992).
The MTD of a weekly (30 min infusion) schedule every 3
weeks, with courses of gemcitabine repeated monthly, was
790 mg m-2 with myelotoxicity being dose limiting (Ab-
bruzzese et al., 1991).
Phase II studies of gemcitabine given as a 30 min infusion
at doses of 800-1250 mg m-2 weekly for 3 weeks have
shown reproducible, independently validated response rates
of 20% in non-small-cell lung cancer (Abratt et al., 1994;
Anderson et al., 1994).
In an attempt to increase cytotoxicity, antimetabolites are
often given as a continuous infusion. In this phase I study we
determined the MTD and toxicity profile of gemcitabine
when given as a 24 h infusion weekly for 3 weeks in patients
with inoperable NSCLC.
Patients and methods
The study was conducted according to the Declaration of
Helsinki and existing rules for good clinical practice (CPMP
Working Party, 1990) and the protocol was approved by the
local ethics committees. Patients with inoperable TNM stage
IIIa, IIlb or IV (Mountain, 1986) adenocarcinoma or
squamous cell carcinoma of the bronchus, aged 18-75 years
were entered into the study after giving informed consent.
Criteria for entry into the study included no prior
chemotherapy, measurable or evaluable disease, WHO
performance status of 0-2, a life expectancy of 12+ weeks,
no radiotherapy or steroid therapy within 3 weeks of study
entry, a leucocyte count of >4.0 x 109 1-', platelets
> 100 x 109 1 - and haemoglobin >10 g 1-'. Exclusion
criteria included active infection, brain metastases, hypercal-
caemia, second malignancy, serum creatinine >0.15
mmol 1-1, serum bilirubin > twice upper limit of normal,
aspartate transaminase >3 x normal and prothrombin time
> 1.5 x normal.
Pretherapy evaluation included documentation of the
patient's history, a medical examination and WHO
performance score. A full blood count, clotting studies,
biochemistry profile, liver function tests, electrocardiograph,
chest radiographs and urinalysis were also routinely
performed. If disease was not measurable clinically or on
chest radiography, a computerised tomography (CT) scan
was performed. Other radiological examinations, e.g. isotope
bone scans, were requested if clinically indicated.
The patient's vital signs and temperature were recorded
before and after each injection ofgemcitabine. Routine blood
tests (FBC, clotting studies, biochemical profile and liver
function tests) and a urinalysis were repeated weekly,
including day 21 when no chemotherapy was given. The
WHO performance score was documented weekly throughout
therapy.
The MTD was defined as the highest dose that could be
safely administered to a patient producing tolerable, manage-
able and reversible toxicity of WHO grade 3 (apart from
nausea, vomiting and alopecia) in at least two of six patients
at a given dose level.
Treatment
The MTD of gemcitabine administered as a 24 h infusion to
mice was 45-60 mg m-2 (Veerman et al., 1994). Gemcitabine
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February 1996is better tolerated in man than mice and 10 mg m-2 was
considered to be a safe starting dose. Three patients were
entered at each dose level.
Dose escalation for the next patient cohort was according
to a modified Fibronachi schedule. Gemcitabine was
dissolved in 0.9% saline and infused over 24 h on days 0, 7
and 14. No therapy was given on day 21. This comprised one
course. Courses of therapy were repeated every 28 days. The
plan was to give a maximum of 4-6 courses of chemo-
therapy.
During each 24 h infusion of gemcitabine the patient's
pulse and blood pressure were monitored every 15 min for
2 h then 2 hourly for 22 h, then 4 hourly for 24 h.
Temperature was monitored at 4 hourly intervals.
Response to therapy was assessed by standard criteria
after two courses of gemcitabine and toxicity documented
according to WHO grade (Miller et al., 1981). Patients whose
disease was responding or stable continued therapy for a
maximum of six courses.
Results
Between March 1992 and July 1994, 24 patients were entered
into this two-centre study. Patient characteristics are shown
in Table I. There were 16 males and 8 females with a median
age of 51 years. Twenty-one patients had a WHO per-
formance score of 1 and the remaining three a score of 2. The
TNM stage was IlIa (6 patients), IlIb (10 patients) and IV (8
patients).
Tables II and III show the results of haematological and
non-haematological toxicity by dose level for each patient at
that dose. A total of 76 courses have been given with doses
ranging from 10-210 mg m- .
Haematological toxicity was mainly neutropenia. Two of
three patients at 210 mg m-2 had grade 3 leucopenia and one
of these also had grade 4 neutropenia. At 180 mg m-2 four
of six patients had grade 3 neutropenia. Infection was not a
problem at 180 mg m-2 but two patients at 210 mg m-2
received intravenous antibiotics. The MTD was determined
to be 180 mg m
WHO grade 3 nausea and vomiting was seen at
20 mg m-2 and subsequent dose levels but was tolerable
and managed with antiemetics. Only two patients required
5HT3 antagonists.
Transient elevations of transaminases were seen at doses
>40 mg m-2, but were not dose limiting. Of all 24 patients


































Phase I study of gemcitabine in NSCLC
H Anderson et al M
461
in the study, non reported WHO grade 3 alopecia, ten (42%)
patients had WHO grade 1 alopecia and one (4%)
experienced WHO grade 2 hair loss.
Lethargy was documented as CNS toxicity-state of
consciousness. It was reported by 16 (67%) patients (WHO
grade 1, n =5; grade 2, n=7; grade 3, n =4) and first noticed
at the dose level of 40 mg m-2. At 180 mg m-2 five of six
patients reported lethargy. At 210 mg m-2 one patient
withdrew because of lethargy.
Mucositis was observed in 15/21 (71%) patients. Twelve
patients had WHO grade 1, two WHO grade 2 and one
WHO grade 3 mucositis. None had grade 4 toxicity. The
patient with WHO grade 3 toxicity had two episodes of
mucositis associated with herpes simplex infection which were
treated with acyclovir.
Transient, asymptomatic hypotension that did not need
medical intervention was reported as an adverse event in 11
(50%) patients. One additional patient received intravenous
fluids for asymptomatic hypotension that occurred at night.
Subsequent monitoring before chemotherapy showed an
asymptomatic nocturnal blood pressure recording of 70/47.
Mild fever (WHO grade 1 or 2) documented in hospital
during routine recording of 4 hourly temperature was
attributed to gemcitabine in 16 (67%) patients. Mild flu-like
symptoms were reported by nine (38%) patients.
Transient skin rash (WHO grade 1 and 2) was seen in ten
patients commencing at the 40 mg m-2 dose level. One
patient discontinued therapy after two courses because of
grade 2 rash which became more extensive (affecting face,
neck, trunk and upper limbs) after the second course of
therapy.
Five patients (21%) achieved a partial response lasting 10,
14, 18, 47 and 51 +weeks. They were observed at the
following dose levels 80 mg m-2, n= 1; 120 mg m-2, n= 1;
180mgm-2, n=2; 210mgm-2, n=1.
The reasons for the discontinuation of gemcitabine were
adverse events, n=3 (pulmonary embolism in patient no.3,
drug rash in patient no.15 and lethargy in patient no.22);
progressive disease, n=6; completion of four or more
planned courses, n= 12.
Discussion
The MTD of gemcitabine when administered as a 24 h
infusion was 180 mg m-2. The main toxicity was neutropenia
and lethargy. Neutropenia was short-lived, and in two cases
at a dose of 210 mg m-2 patients received intravenous
antibiotics. Although four of six patients treated at
180 mg m-2 developed WHO grade 3 neutropenia none
required intravenous antibiotics. Neutropenia could be
prevented by granulocyte colony-stimulating factor (G-
CSF). However, lethargy was a frequent toxicity of
gemcitabine when administered as a 24 h infusion. One
patient (at 210 mg m-2) withdrew from the study because of
lethargy (WHO grade 2 CNS toxicity-somnolence for
<50% of waking hours) because it was continuous and
Table II Haematological toxicity by patient and dose level
Dose No. of No. of WHO toxiCitya
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Table III Non-haematological toxicity by patient and dose level
Dose No. of No. of WHO toxicity
(mg m-2) patients courses N/V Hair Creatinine Alt Oral Lethargy
10 3 5 0,0,1 0,0,0 0,0,0 0,0,0 0,0,0 0,0,0
20 3 9 1,3,0 0,1,0 0,0,0 0,0,0 0,0,1 0,0,0
40 3 12 1,1,3 0,0,0 0,0,0 0,0,2 0,0,1 2,0,3
80 3 13 3,3,3 1,1,0 0,0,0 0,1,0 1,0,1 1,3,1
120 3 7 3,1,3 1,0,1 0,0,0 2,2,3 1,1,2 2,1,3
180 6 20 3,1,3 0,1,1 0,0,0 2,2,3 1,1,1 3,1,1
3,3,3 1,0,1 0,0,0 2,2,2 3,1,0 2,2,0
210 3a 10 3,1,0 1,0,2 0.0.0 1,1,3 1,1,2 2*,2,2
aPatient no. 22 withdrew because oflethargy.
'destroyed my quality of life'. Lethargy occurred in five of six
patients at the MTD. In the WHO definition of CNS toxicity
grade 3 somnolence is for more than 50% of waking hours.
Grade 2 or 3 toxicity can be tolerated for short periods, but
is unacceptable when prolonged.
Gemcitabine was otherwise well tolerated with no
alopecia. Transient WHO grade 3 nausea and vomiting
occurred in 13/24 (54%) patients in the study, and five of six
patients at the MTD.
The phase I study of a daily x 5 schedule showed that
hypotension, fever and flu-like symptoms were dose-limiting
toxicities (O'Rourke et al., 1994). In this study ofgemcitabine
administered over 24 h symptomatic hypotension was not a
clinical problem. Mild fever was seen in 67% patients and flu
symptoms in 38% patients.
In our previous study of gemcitabine administered as a
30 min infusion fever was seen in 32% patients and lethargy
in 38% patients (Anderson et al., 1984). These toxicities were
doubled with the 24 h infusion schedule. In addition,
vomiting was more common with the 24 h infusion 54% vs
38%. Mucositis was observed in 15/21 (71%) patients in this
24 h infusion study compared with 12% patients treated on a
30 min infusion. The incidence of flu-like symptoms was
similar in the two studies.
This phase I study has shown the MTD of 24 h
gemcitabine infusion to be 180 mg m-2 in patients who had
not received prior chemotherapy. At this dose the WHO
grade 3 neutropenia in four of six patients was transient and
not associated with infection. Two of these four patients had
WHO grade 3 leucopenia.
Although this was a phase I study involving only 24
patients, 13 of whom were treated at a dose below the MTD,
partial tumour response was seen in five (21%) patients. The
duration of response ranged from 10-51 + weeks. However,
the symptomatic toxicity, especially lethargy observed with
this 24 h infusion schedule was greater than that reported
with the more convenient 30 min infusion schedule which has
the potential for outpatient administration (Anderson et al.,
1994; Abratt et al., 1994).
Acknowledgement
This phase I study was supported by Eli Lilly and Company.
References
ABBRUZZESE JL, GRUNEWALD R, WEEKS EA, GRAVEL D, ADAMS
T, NOWAK B, MINEISHI S, TARASSOFF P, SATTERLEE W AND
RABNER NM. (1991). A phase I clinical, plasma and cellular
pharmacology study ofgemcitabine. J. Clin. Oncol., 9, 491-498.
ABRATT RP, BEZWODA WR, FALKSON G, GOEDHALS L, HACKING
D AND RUGG TA. (1994). Efficacy and safety profile of
gemcitabine in non-small cell lung cancer: a phase II study. J.
Clin. Oncol., 12, 1535-1540.
ANDERSON H, LUND B, BACH F, THATCHER N, WALLING J AND
HANSEN HH. (1994). Single agent activity ofweekly Gemcitabine
in advance non-small cell lung cancer: a phase II study. J. Clin.
Oncol., 12, 1821-1826.
CPMP WORKING PARTY ON EFFICACY OF MEDICINAL PRO-
DUCTS. (1990). EEC note for guidance: good clinical practice
for trials on medicinal products in the European Community.
Pharmacol. Toxicol., 67, 361 -372.
HEINEMANN V, HERTEL LW, GRINDEY GB AND PLUNKETT W.
(1988). Comparison ofthe cellular pharmacokinetics and toxicity
of 2' 2' difluorodeoxycytidine and 1-B-D-arabinofuranosylcyto-
sine. Cancer Res., 48, 4024-2031.
HERTEL LW, BODER GB, KROIN JS, RINZEL SM, POORE GA, TODD
GC AND GRINDEY GB. (1990). Evaluation of the antitumour
activity of gemcitabine (2', 2'-difluoro-2'-deoxycytidine). Cancer
Res., 50, 4417-4422.
HUANG P, CHUBB S, HERTEL LW, GRINDEY GB AND PLUNKETT
W. (1991). Action of 2'2' difluorodeoxycytidine on DNA
synthesis. Cancer Res., 51, 6110-6117.
MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A.
(1981). Reporting the results of cancer treatment. Cancer, 47,
207-214.
MOUNTAIN CF. (1986). A new international staging system for lung
cancer. Chest, 89, (suppl.) 225-233.
O'ROURKE TJ, BROWN TD, HAVLIN K, KUHN JG, CRAIG JB,
BURRIS HA, SATTERLEE WG, TARASSOFF PG AND VON HOFF
DD. (1994). Phase I clinical trial of gemcitabine given as an
intravenous bolus on 5 consecutive days. Eur. J. Cancer, 30A,
417-418.
POPLIN EA, CORBETT T, FLAHERTY L, TARASOFF P, REDMAN BG,
VALDIVIESO M AND BAKER L. (1992). Difluorodeoxycytidine
(dFdC)-gemcitabine: a phase I study. Invest. New Drugs, 10,
165-170.
VEERMAN G, RUIZ VAN HAPEREN V AND VERMORKEN JB. (1994).
Superior therapeutic activity of prolonged compared with bolus
administration of2'2' difluorodeoxycytidine (gemcitabine) in vivo
against murine colon tumours. In Biochemical Pharmacology of
Gemcitabine (2'2' difluorodeoxycytidine). Ruiz van Haperen VU
(ed.), 9, pp. 189- 206. University Press: Amsterdam.
XU YZ AND PLUNKETT W. (1990). Regulation ofdCMP deaminase
in intact CCRF-CEM cells. Proc. Am. Assoc. Cancer Res., 30,
abstract 2402.